Caligan Partners LP 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Caligan Partners LP disclosed 16 US equity positions worth $720.7m in its Q3 2025 13F filing. The largest position was LQDA at 25.6% of the reported book, followed by ABVX and MLYS. Against the Q2 2025 filing, it opened 5 new positions, added to 6 and reduced 2 among the top 16 holdings.
What did Caligan Partners LP own in Q3 2025? Top 16 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | LQDA LIQUIDIA CORPORATION | Healthcare | 25.6% | $184.6m | 8,118,892 | 0% | held |
| 2 | ABVX ABIVAX SA | 17.1% | $123.3m | 1,451,924 | -13% | reduced | |
| 3 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 14.6% | $105.1m | 2,772,654 | 37% | added |
| 4 | EXEL EXELIXIS INC | Healthcare | 8.7% | $63.0m | 1,525,730 | 0% | held |
| 5 | RVMD REVOLUTION MEDICINES INC | Healthcare | 6.9% | $49.7m | 1,064,249 | 67% | added |
| 6 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 6.3% | $45.4m | 1,131,205 | 6% | added |
| 7 | ADMA ADMA BIOLOGICS INC | Healthcare | 5.4% | $38.7m | 2,636,609 | – | new |
| 8 | EOLS EVOLUS INC | Healthcare | 3.5% | $25.4m | 4,138,943 | 24% | added |
| 9 | MERUS N V | 2.8% | $20.4m | 216,954 | -67% | reduced | |
| 10 | XENE XENON PHARMACEUTICALS INC | Healthcare | 2.5% | $17.8m | 444,565 | – | new |
| 11 | ANIK ANIKA THERAPEUTICS INC | Healthcare | 1.9% | $13.5m | 1,435,130 | 0% | held |
| 12 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.5% | $10.6m | 833,333 | – | new |
| 13 | TYRA TYRA BIOSCIENCES INC | Healthcare | 1.4% | $9.7m | 696,825 | 267% | added |
| 14 | INBX INHIBRX BIOSCIENCES INC | 1.1% | $8.0m | 236,383 | – | new | |
| 15 | VRCA VERRICA PHARMACEUTICALS INC | 0.6% | $4.0m | 923,910 | – | new | |
| 16 | AURA AURA BIOSCIENCES INC | 0.2% | $1.4m | 227,174 | 14% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.